Zobrazeno 1 - 10
of 587
pro vyhledávání: '"Bcl-2 inhibitor"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract The rapid development of high-throughput sequencing in recent years has facilitated great progress in the molecular-targeted therapy of hematological malignancies, including leukemia, lymphoma, and multiple myeloma. BCL-2 inhibitors are amon
Externí odkaz:
https://doaj.org/article/71265a18a9e34aea88eae49e18eb9766
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 1771-1784 (2024)
Yinyu Zhao,1,2 Nan Guo,1,3 Yidan Zhu,1,2 Jingyuan Shang,4 Jiali Chen,1,3 Xingxian Luo,1 Yi Liu,1 Xiaohong Zhang,1 Lin Huang1 1Department of Pharmacy, Peking University People’s Hospital, Beijing, People’s Republic of China; 2School of Pharmaceuti
Externí odkaz:
https://doaj.org/article/e96dde89b41c44b69e8600c834868027
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionVenetoclax is a BCL-2 inhibitor with proven efficacy in patients with multiple myeloma (MM) and translocation t(11;14). However, its role in plasma cell leukemia (PCL) remains unclear. Herein, we aimed to report a case of relapsed MM with
Externí odkaz:
https://doaj.org/article/470c774a7af44ec1ad222975166f1030
Publikováno v:
Annals of Medicine, Vol 55, Iss 1, Pp 1029-1036 (2023)
AbstractBackground Multiple myeloma (MM) is an incurable malignancy. Venetoclax (VEN) shows a meaningful effect in MM patients who are relapsed or refractory (RR) to previous standard therapies.Objective This study aimed to assess the efficacy and sa
Externí odkaz:
https://doaj.org/article/d43ab4679ea642508234c89e60223860
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol Volume 16, Pp 401-405 (2023)
Yan Wu,1 Shan Liu,1 Dongmei Wang,1 Xinjie Yao2 1Department of Hematology, The Harison International Peace Hospital Affiliated to Hebei Medical University, Hengshui, Hebei, 053000, People’s Republic of China; 2Department of Clinical Laboratory, The
Externí odkaz:
https://doaj.org/article/8d9eeb198d024fa88719681927155a29
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTBackground: T-prolymphocytic leukemia (T-PLL) is an aggressive hematologic malignancy. A portion of patients can be cured with alemtuzumab induction followed by allogeneic hematopoietic stem cell transplant, but patients who relapse after tra
Externí odkaz:
https://doaj.org/article/2fab398806a24985a9f7976cb6305edf
Autor:
Andrés Gómez-De León, Roberta Demichelis-Gómez, Alfredo Pinedo-Rodríguez, Daniel Enriquez-Vera, Juan Antonio Flores-Jiménez, Adrián Alejandro Ceballos-López, Margarita Rodríguez-Mejorada, Miguel Angel Herrera Riojas, Roberto Ovilla-Martínez, Pamela Báez-Islas, Xóchitl Cota-Rangel, Yvette Neme-Yunes, Sergio Inclán-Alarcón, Nelson J. López-Flores, Perla R. Colunga-Pedraza, Anna C. Rodríguez-Zúñiga, David Gómez-Almaguer
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 249-257 (2022)
Objectives: Venetoclax combinations are a new standard for patients with acute myeloid leukemia (AML). We aimed to evaluate the safety and efficacy of these combinations in a period of accelerated approval in Latin-America. Methods: This observationa
Externí odkaz:
https://doaj.org/article/432b0ee68d524155a471093605e2ce2c
Autor:
Natalia Timofeeva, Mary L. Ayres, Natalia Baran, Janice M. Santiago-O’Farrill, Gamze Bildik, Zhen Lu, Marina Konopleva, Varsha Gandhi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionChronic lymphocytic leukemia (CLL) cells are metabolically flexible and adapt to modern anticancer treatments. Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors have been widely used to treat CLL, but CLL cells become
Externí odkaz:
https://doaj.org/article/5f4424f292934236ac1ccec24c8ba64a
Autor:
Anna Ferrari, Delia Cangini, Andrea Ghelli Luserna di Rorà, Annalisa Condorelli, Marta Pugliese, Giovanni Schininà, Sebastiano Cosentino, Eugenio Fonzi, Chiara Domizio, Giorgia Simonetti, Salvatore Leotta, Giuseppe Milone, Giovanni Martinelli
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
High-risk relapsed/refractory adult Philadelphia-negative (Ph−) B-cell acute lymphoblastic leukemia (B-ALL) is a great challenge due to limited possibilities to achieve and maintain a complete response. This also applies to cases with extramedullar
Externí odkaz:
https://doaj.org/article/bc12e74fa7e04b59af26cedd0981c4a3